Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab for AF recurrence prevention (CONVERT-AF)
NCT01805960Phase 2Terminated
- Sponsor
- University Hospital Basel
- Start
- Jun 2013
- Primary completion
- Dec 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of canakinumab in Atrial fibrillation (AFib), sponsored by University Hospital Basel. Started Jun 2013; status: terminated.
02
Drugs
canakinumab
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT01805960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01805960.